Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Duality Biologics

- PMLiVE

Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

Avalere Health

- PMLiVE

Researchers at ICR London discover new nutrient source for cancer growth

Study reveals new findings of dietary changes within pancreatic cancer cells

- PMLiVE

AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer

An estimated 2.2 million people worldwide are diagnosed with lung cancer each year

- PMLiVE

Bristol Myers Squibb and Tubulis partner in deal worth over $1bn

The agreement is aimed at developing differentiated ADCs for solid tumours

- PMLiVE

ICR and NeoPhore announce immuno-oncology collaboration to develop new cancer drugs

The partners will evaluate the effect of NeoPhore’s small molecule inhibitors on tumours

- PMLiVE

Authorisation for Moderna and Pfizer/BioNTech’s bivalent COVID-19 vaccines simplified by FDA

The vaccines are now authorised for all doses in individuals aged six months and older

- PMLiVE

Incyte and Biotheryx collaborate to develop protein degraders for oncology targets

Biotheryx will receive up to $347m in potential milestone payments

- PMLiVE

BioNTech and Duality Biologics partner in deal worth over $1.5bn

The companies will co-develop two antibody-drug conjugates for solid tumours

- PMLiVE

Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies

The deal to develop a small-molecule inhibitor could be worth over $480m

- PMLiVE

BioNTech reveals plans to spend about €1bn more on research and development this year

The company has already started clinical trials assessing four new infectious disease vaccines

- PMLiVE

FDA proposes improvements for oncology clinical trials supporting accelerated approval

The draft guidance discusses the advantage of randomised clinical trials over single-arm studies

- PMLiVE

Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children

The companies have also submitted an application to the EMA for this age group

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links